KALA BIO, Inc. Files 8-K/A Amendment
Ticker: KALA · Form: 8-K/A · Filed: Oct 2, 2025 · CIK: 1479419
Sentiment: neutral
Topics: amendment, executive-changes, disposal-activities
TL;DR
KALA BIO filed an 8-K/A amendment covering executive changes and disposal costs.
AI Summary
KALA BIO, Inc. filed an 8-K/A amendment on October 2, 2025, related to events occurring on September 28, 2025. The filing pertains to cost associated with exit or disposal activities, departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. It also includes financial statements and exhibits.
Why It Matters
This amendment to KALA BIO's 8-K filing indicates potential restructuring, executive changes, or disposal activities that could impact the company's future operations and financial health.
Risk Assessment
Risk Level: medium — Amendments to 8-K filings, especially those involving executive departures and disposal activities, can signal significant operational or strategic shifts that carry inherent business risks.
Key Players & Entities
- KALA BIO, Inc. (company) — Registrant
- September 28, 2025 (date) — Earliest event reported
- October 2, 2025 (date) — Filing date
FAQ
What specific exit or disposal activities are being reported by KALA BIO, Inc.?
The filing indicates 'Cost Associated with Exit or Disposal Activities' as an item of information, but the specific details of these activities are not provided in the excerpt.
Are there any changes in the board of directors or executive officers at KALA BIO, Inc. as of September 28, 2025?
Yes, the filing lists 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' as an item of information, suggesting potential changes.
What is the purpose of filing an 8-K/A amendment?
An 8-K/A is an amendment to a previously filed Current Report on Form 8-K, used to correct or supplement information previously reported.
When was KALA BIO, Inc. incorporated and what is its principal business address?
KALA BIO, Inc. was incorporated in Delaware and its principal business address is 1167 Massachusetts Avenue, Arlington, MA 02476.
Does this filing include any information about compensatory arrangements for officers?
Yes, the filing explicitly mentions 'Compensatory Arrangements of Certain Officers' as an item of information being reported.
Filing Stats: 1,169 words · 5 min read · ~4 pages · Grade level 13.2 · Accepted 2025-10-02 16:15:38
Key Financial Figures
- $0.001 — e on which registered Common Stock, $0.001 par value per share KALA The Nasdaq C
- $0.4 million — expects to incur costs of approximately $0.4 million related to the Reduction, primarily con
- $183,750 — ayment (each, a "Retention Payment") of $183,750, $136,250, and $145,000, respectively.
- $136,250 — ch, a "Retention Payment") of $183,750, $136,250, and $145,000, respectively. Each of th
- $145,000 — on Payment") of $183,750, $136,250, and $145,000, respectively. Each of the Retention Ag
Filing Documents
- tm2527808d1_8ka.htm (8-K/A) — 30KB
- tm2527808d1_ex10-1.htm (EX-10.1) — 12KB
- tm2527808d1_ex10-1img001.jpg (GRAPHIC) — 10KB
- 0001104659-25-096071.txt ( ) — 221KB
- kala-20250928.xsd (EX-101.SCH) — 3KB
- kala-20250928_lab.xml (EX-101.LAB) — 33KB
- kala-20250928_pre.xml (EX-101.PRE) — 22KB
- tm2527808d1_8ka_htm.xml (XML) — 3KB
02
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 2, 2025, the Company entered into retention agreements (each, a "Retention Agreement") with Todd Bazemore, the Company's President and Chief Executive Officer, Mary Reumuth, the Company's Chief Financial Officer, and Kim Brazzell, Ph.D., the Company's Head of Research and Development and Chief Medical Officer. Pursuant to the terms of their respective Retention Agreements, Mr. Bazemore, Ms. Reumuth and Dr. Brazzell are entitled to receive retention payment (each, a "Retention Payment") of $183,750, $136,250, and $145,000, respectively. Each of the Retention Agreements provides that if, prior to December 31, 2025, such executive's employment is terminated voluntarily by such executive or by the Company for cause (as defined in the applicable executive's employment agreement), then, pursuant to the terms of the Retention Agreement, such executive shall, upon request, repay the gross amount of the Retention Payment to the Company. The foregoing description of the Retention Agreements is not complete and is qualified in its entirety to the full text of the Form of Retention Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference. Cautionary Note Regarding Forward Looking Statements contained in this Current Report on Form 8-K regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the Company's plans to evaluate its strategic options, preserve cash and implement the Reduction and the es
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. 10.1 Form of Retention Agreement 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KALA BIO, INC. Date: October 2, 2025 By: /s/ Mary Reumuth Mary Reumuth Chief Financial Officer and Corporate Secretary